Diabetes Clinical Trials in Illinois

Showing 141-160 of 608 trials

VasQ External Support for Arteriovenous Fistula

NCT03242343

This is a prospective clinical study of the VasQ external support for arteriovenous fistulas. The device is designed to improve fistula outcomes by optimizing the geometrical configuration of the fistula, influencing hemodynamics, minimizing turbulence and promote laminar flow. All patients will be implanted with the VasQ device and will be followed up for a duration of 24 months.

Arterio-Venous FistulaESRDSteal Syndrome+5 more

Laminate Medical Technologies144 participantsStarted Nov 2017

Birmingham, Alabama, United States • Phoenix, Arizona, United States • Peoria, Illinois, United States +12 more locations

COMPLETEDPhase 3125 miles

Gan & Lee Insulin Glargine Target Type (1) Evaluating Research

NCT03371082

Primary Objective: •To evaluate equivalence of Gan \& Lee Insulin Glargine Injection and Lantus® in terms of immunogenicity Secondary Objective: Immunogenicity: • To evaluate the percentage of subjects with negative anti-insulin antibodies (AIAs) at baseline who develop confirmed positive AIA up to Week 26, the percentage of baseline in AIA titers between treatment groups, the percentage of subjects with confirmed positive AIA who develop any anti-insulin neutralizing antibodies up to visit Week 26, and percentage of subjects who develop confirmed positive AIA up to visit Week 26 of Gan \& Lee Insulin Glargine Injection in comparison with that of Lantus®. Safety: •To evaluate the safety of Gan \& Lee Insulin Glargine Injection in comparison with that of Lantus®. Efficacy: •To evaluate the efficacy of Gan \& Lee Insulin Glargine Injection in comparison with that of Lantus®.

Diabetes Mellitus, Type 1

Gan and Lee Pharmaceuticals, USA576 participantsStarted Oct 2017

Birmingham, Alabama, United States • Fresno, California, United States • Newport Beach, California, United States +82 more locations

VasQ External Support for Arteriovenous Fistula

Gan & Lee Insulin Glargine Target Type (1) Evaluating Research

Diabetes Trials in Other Cities

Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab

Validation Study of RETINA-AI Galaxy™ v2.0, an Automated Diabetic Retinopathy Screening Device

Pathway for Produce Prescriptions in Diabetes Management

Pivotal Trial of a Digital Therapeutic for the Treatment of Type 2 Diabetes

Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer): Extension Study

The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants

Longitudinal Observation of Insulin Requirements and Sensor Use in Pregnancy

Control-IQ Technology in Individuals With Type 2 Diabetes

Pregnancy Intervention With a Closed-Loop System (PICLS) Study

Omnipod Horizon™ Automated Glucose Control System Preschool Cohort

The Effect of In-utero Exposure to Metformin in 5-11 Year Old Offspring of Mothers in the MiTy Trial

Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration Trial

Rapid, Non-invasive, Regional Functional Imaging of the Retina. (Diabetic Retinopathy Diagnosis Device)

A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes

Diabetes Pump With Predictive Low Glucose Suspend Pivotal Trial

Other Conditions in Illinois